Unleashing Potential for Over 100 Years

Sold all shares of Ajinomoto Althea.

Ajinomoto Bio-Pharma Services acquires Forge Biologics, a North American gene therapy CDMO company.

Ajinomoto Bio-Pharma Services completes the acquisition of Granules OmniChem Private Limited joint venture in India. The addition of Ajinomoto Bio-Pharma Services India Pvt. Ltd strengthens Aji Bio-Pharma’s commitment to providing its clients accessibility to a reliable and simplified CDMO supply chain across all sites globally.

GeneDesign Inc., a wholly owned Ajinomoto company in Osaka, Japan and provider of high quality and scalable custom oligonucleotides, joins Ajinomoto Bio-Pharma Services, strengthening the organization’s commitment to its customers to be a leading global CDMO with comprehensive capabilities.

Ajinomoto Althea and OmniChem unite their world-class capabilities to form Ajinomoto Bio-Pharma Services, a fully integrated, global CDMO with facilities in the United States and Belgium.

Launch of continuous flow technology for small molecule API commercial manufacturing at the OmniChem Wetteren, Belgium facility.

Expansion of HPAPI capabilities at the OmniChem Wetteren site.

Establishment of Granules OmniChem (a 50:50 JV with Granules India Limited) for the bulk manufacturing of both intermediates and APIs.

Althea and its San Diego production facilities acquired by Ajinomoto Co., Inc.

HPAPI production at OmniChem’s Wetteren site begins, with the construction of a dedicated facility to allow the safe handling and manufacturing of HPAPIs and cytotoxic products.

Commencement of new purification plant for botanical extracts at the OmniChem Wetteren site.

Diversification of OminChem’s Balen (Belgium) site allowed for production of APIs and pharmaceutical intermediates.

OmniChem and its Belgian production facilities acquired by Ajinomoto Co., Inc.

The production of synthetic intermediates and bulk actives for the pharmaceutical industry began at the Wetteren facility.

The Wetteren site progressively added the production tannic acid and botanical extracts.

Wetteren, Belgium (future OmniChem) production site founded to manufacture black powder.